Updates on the iNTEGRATE and ROCKstar Trials
April 23rd 2024Yi-Bin Chen, MD, provides an overview of the iNTEGRATE and ROCKstar trials, underscoring their significance in the current treatment paradigm for graft versus host disease, particularly highlighting their ability to inhibit the fibrosis cascade, which offers substantial benefits for patient healing and recovery.
Watch
Behind the CheckMate-77T Trial of a Nivolumab-Based Regimen in NSCLC
April 19th 2024Tina Cascone, MD, PhD, discusses the CheckMate-77T trial of perioperative regimen of neoadjuvant nivolumab plus chemotherapy followed by surgery and adjuvant nivolumab for the treatment of patients with stage IIA to IIIB non-small cell lung cancer.
Watch
Case 1: Therapeutic Sequencing for Relapsed/Refractory Metastatic Clear Cell RCC
Sumanta Kumar Pal, MD, FASCO, presents the case of a 66-year-old man with metastatic renal cell carcinoma, and the panel provides comprehensive insights on treatment decisions, highlighting the NCCN Guidelines.
Watch
Renal Cell Carcinoma: Risk Stratification and Evolving Treatment Landscape
A panel of 4 experts on renal cell carcinoma introduce themselves and discuss IMDC risk stratification criteria and the evolution of the treatment landscape.
Watch
Setting Expectations + First-Line and Second-Line Treatment of Graft Versus Host Disease
April 16th 2024A medical professional outlines the goals and challenges of communicating with his patient, emphasizing the importance of setting realistic expectations for halting disease progression and potentially achieving some degree of disease reversibility, while also exploring the roles of first-line and second-line therapies in the management of chronic graft versus host disease.
Watch
Patient Case: Pathology of Graft Versus Host Disease
April 16th 2024Yi-Bin Chen, MD, presents a patient case, detailing the symptomology and pathology of graft versus host disease, such as dry eyes, dry mouth, and difficulty swallowing, while also addressing steroid dependence as an indication for initiating second-line therapy.
Watch
Future Landscape of BPDCN Management
April 15th 2024Dr. Schiller will discuss the limitations of current treatment options for BPDCN in elderly transplant-ineligible patients and the emerging BPDCN research and data that they are most interested in to improve outcomes in this specific patient population.
Watch
Improving BPDCN Recognition and Diagnosis
April 15th 2024Dr. Schiller will discuss the red flag symptoms that increase suspicion of BPDCN, the process for diagnosis, and any challenges with differential diagnosis. Dr. Schiller will also provide strategies and resources to improve community recognition and diagnosis of this rare disease.
Watch
Current Therapies and Strategies for Transplant-Ineligible BPDCN Patients
April 15th 2024Dr. Schiller will discuss the limitations of currently available BPDCN treatments, the historical use of chemotherapy regimens and their potential to address unmet needs, and effective strategies for managing the financial burden and ensuring access to tagraxofusp for BPDCN patients.
Watch
Challenges and Unmet Needs in Transplant-Ineligible BPDCN Patients
April 15th 2024Dr. Schiller will discuss the key factors that make the transplant ineligible BPDCN patient population more difficult to treat, the major goals of therapy for these patients, and how the mechanism of action of tagraxofusp suggests potential efficacy in BPDCN.
Watch